[Intervention with clarithromycin in patients with stable coronary heart disease--the CLARICOR trial: secondary publication].
Antibiotics may reduce cardiovascular morbidity. We randomised 4372 patients with stable coronary heart disease in the CLARICOR trial to clarithromycin 500 mg (n = 2172) or placebo (n = 2200) daily for a fortnight. After 2.6 years we found significantly increased cardiovascular mortality among the clarithromycin patients. There is a need for studies to evaluate the safety of clarithromycin. There is presently no evidence to support the preventive effect of antibiotics on patients with coronary heart disease.
Copenhagen Trial Unit (CTU), Center for Klinisk Interventionsforskning, Rigshospitalet, DK-2100 København Ø. cgluud@ctu.rh.dk.